Patrick Ma, M.D., recently spoke at the World Non-Small-Cell Lung Cancer (NSCLC) Summit in Boston, with a presentation titled, "MET Targeted Therapy in NSCLC." Dr. Ma is the co-leader of the Sara Crile Allen and James Frederick Allen Comprehensive Lung Cancer Program at the Mary Babb Randolph Cancer Center,
The Allen Lung Cancer Program will also have a major presence at the 16th World Conference on Lung Cancer Sept. 6-9 in Denver. Several abstracts submitted by the program have been accepted for presentation.
Ma will make two major oral presentations and two mini oral presentations.
- The title of the major oral presentations are "Whole Exome Sequencing to Profile the Genomic Landscapes of Young Patients Diagnosed with NSCLC." WVU co-authors include Xiaoliang Wu, Wei Zhang and Scot Remick, M.D.
- The title of the second major oral presentation is "ALK-Rearranged NSCLC Adaptive Cell Plasticity with Early Onset TGFb2 Mediated Precision Drug Escape through PRC-2 Epigenetic Reprogramming." WVU co-authors include Wu and Zhang.
- One of the mini oral presentations is titled "Transcriptome-Metabolome Reprogramming of EGFR-Mutant NSCLC Contributes to Early Adaptive Drug-Escape via BCL-xL Mitochondrial Priming." WVU co-authors are Wu and Zhang.
- The second mini oral presentation is titled "Circulating Tumor Cells (CTC) Enrichment as Liquid-Biopsy for Molecular and Genomic Characterization in ALK-Rearranged (ALK+) Lung Cancer." WVU co-author is Zhang.
The program will also present a poster titled "Quantitative Immunofluorescence Based Expression Analysis in NSCLC Reveals Nuclear EZH2 as Poor Prognostic Biomarker." WVU authors include Sijin Wen, Ph.D., Zhang and Ma.
In addition, hematology oncology fellow graduate Abdul Rahman Alshehri, M.D., will make a mini oral presentation titled "Quantitative Mass Spectrometry Proteomics Identifies FRalpha and GARFT as Predictive Biomarkers in NSCLC Patients Treated With Pemetrexed." WVU’s Manish Monga, M.D., is last author, and Ma is co-author.
The World Conference on Lung Cancer is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies.
WVU Cancer Institute's Cancer Prevention and Control, in collaboration with the West Virginia Cancer Registry, has released the 2017 Cancer Burden Report. The report provides updated statewide, age-adjusted incidence rates and counts for cancer diagnosed among West Virginia residents from 2010 to 2014.
The West Virginia Breast and Cervical Cancer Screening Program (WVBCCSP), a program of WVU Cancer Institute Cancer Prevention and Control, has designated January 12 as Wear Teal Day in observance of cervical cancer awareness across the state. Each year in West Virginia, approximately 97 women are diagnosed and 37 women die of cervical cancer, according to the West Virginia Cancer Burden Report for 2017. The publication points out that while these numbers are small, West Virginia ranks in the top five for both cervical cancer incidence and mortality when compared with other states, and more than half of the women with cervical cancer in the state are diagnosed at an advanced stage. The good news is that most cervical cancer can be prevented by screening with Pap and Human Papillomavirus (HPV) tests and HPV vaccination. The WVBCCSP helps uninsured and underinsured women gain access to free or low-cost cervical cancer and breast cancer screening services.
This six-week series will equip participants with mindfulness tools and techniques geared towards achieving greater focus and resiliency, whether academically or in the workplace.